-
Wellgistics Health issues $21M convertible debt, raises $6.5M new capital, refinances all outstanding convertible debt
New $21M oversubscribed convertible debt refinances all outstanding convertible debt; no interest; converts at $6.00/share.
-
Wellgistics Health raises $16.9M via convertible notes at 20% OID; majority shareholders lock up shares
Notes aggregate principal $21.1M for $16.9M cash (20% OID); zero interest; mature in 12 months.
-
Wellgistics Health announces strategic moves: DelivMeds AI, QOLPOM patents, Tollo Health stake, and share restructuring
Expanded Datavault license and DelivMeds AI create IP for tokenized healthcare data management via EinsteinRx™.
-
Wellgistics Health enters binding term sheet for DelivMeds AI; announces 1-for-50 reverse stock split
Binding term sheet with Datavault AI (DVLT), Scilex (SCLX) and others to form DelivMeds AI; combined asset value expected $4B (subject to fairness opinion).
-
Wellgistics Q1 revenue $0.93M, net loss $7.7M; terminates Neuritek/WellCare LOIs; guides Q2 ~$1.78M
Revenue $0.93M in Q1 2026 vs $0.49M Q4 2025; expects Q2 rev $1.78M (with $0.86M recognized through May 18).
-
Wellgistics Health to report Q1 2026 results on May 19 after market close
Wellgistics Health will announce Q1 2026 financial results after market close on Tuesday, May 19, 2026.
-
Wellgistics withdraws preliminary proxy statement; continues evaluating strategic transactions
Filed request with SEC to withdraw Preliminary Proxy Statement on Schedule 14A filed May 14, 2026.
-
Wellgistics Health subsidiary enters forbearance agreement on $1.77M debt
Wellgistics, LLC acknowledges $1.77M owed to Marco Capital under Nov 2024 loan; MCI forbears through June 15, 2026.
-
Wellgistics Health enters Amended Settlement Agreement with Silverback Capital; no terms disclosed
Amended Settlement Agreement with Silverback Capital Corporation dated February 9, 2026.
-
Wellgistics receives Nasdaq deficiency notice; forms JV with KareRx hub
Received Nasdaq deficiency letter on Apr 13, 2026 for failing minimum $2.5M stockholders' equity; equity was -$12.4M.
-
Wellgistics Health forms joint venture with KareRx Hub, issuing up to $2M in stock for 51% stake
Wellgistics holds 51% membership interest in new LLC Healthstar; Kare Rx Hub holds 49%.
-
Wellgistics terminates settlement with Silverback Capital; no further share issuance under Section 3(a)(10)
Company terminated Settlement Agreement with Silverback Capital Inc., effective April 3, 2026.
-
Wellgistics Health issues $1.25M in promissory notes at 20% discount to accredited investors
Company entered Note Purchase Agreement for up to $1,250,000 aggregate principal; purchase price $1,000,000 (20% OID).
-
Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal
Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).
-
Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market
Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.
-
Wellgistics settles $10.7M liabilities via equity at $0.25–$2.25/share; appoints consulting CBO
Settled ~$10.7M liabilities with Silverback Capital via court-approved Section 3(a)(10) share issuance.
-
Wellgistics Health partners with NFL Alumni Health to deploy AI pharmacy tech for former NFL players
Partnership leverages EinsteinRx AI platform and PharmacyChain smart contracts for healthcare optimization.
-
Two directors resign from Wellgistics Health board effective Feb 1, 2026
Steven Lee (Ethics Committee) and Howard Doss (Audit Committee chair) resigned immediately.
-
Wellgistics Health issues up to $8.125M secured convertible notes at 20% OID
Issued $8.125M aggregate principal of secured convertible notes; purchase price $6.5M (20% OID).
-
Wellgistics Health issues $3.125M convertible notes at 20% OID; sets 2026 target of 500 pharmacy onboardings/month
Issued up to $3,125,000 aggregate principal convertible notes; purchase price $2.5M (20% original issue discount).
-
Wellgistics sets Dec 19 record date for Dream Bowl meme coin token distribution
Record date of December 19, 2025 for Dream Bowl 2026 Meme Coin tokens.
-
Wellgistics Health receives Nasdaq bid-price deficiency notice; 180-day cure period through June 8, 2026
Stock closed below $1.00 for 30 consecutive business days (Oct 27–Dec 9, 2025); violates Nasdaq Listing Rule 5550(a)(2).
-
Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market
Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.
-
Wellgistics Health declares stockholder distribution of Dream Bowl 2026 Meme Coin
Record date December 19, 2025; each share receives one Dream Bowl 2026 Meme Coin.
-
Wellgistics licenses DataVault AI smart contract IP for PharmacyChain; $2.5M upfront plus royalties
Upfront license fee of $2.5M due by Dec 31, 2025; ongoing 13% royalty on PharmacyChain net profit.
-
Wellgistics Health sponsors Dream Bowl 2026, plans meme coin airdrop to shareholders
Sponsorship fee of $250,000 for Dream Bowl XIV in Arlington, TX, Jan 8-11, 2026.
-
Wellgistics Health pays $2.5M for exclusive license of DataVault AI patents for PharmacyChain
License fee of $2.5M to DataVault AI, payable by Dec 31, 2025; plus 13% royalty on net profit from PharmacyChain.
-
Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp
Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
-
Auditor UHY resigns citing former CEO resignation info; Suri & Co. re-engaged
UHY LLP resigned as auditor on Nov 11, 2025 due to information from former CEO's resignation not yet investigated.
-
Wellgistics Health issues ~10.7M shares from warrant exercise and debt conversions
On Oct 24, warrant holders exercised 3,111,429 shares at $0.70, raising $2.18M.
-
Wellgistics Health partners with DataVault AI to develop blockchain-based PharmacyChain for prescription drug tracking
SaaS agreement with DataVault AI (NASDAQ: DVLT) to develop PharmacyChain, a manufacturer-to-patient blockchain platform.
-
Wellgistics signs non-binding LOI with DataVault for blockchain pharmacy contract platform
Non-binding LOI to integrate DataVault's blockchain smart contracts (PharmaChain) into Wellgistics' prescription fulfillment network.
-
Wellgistics Health re-appoints Prashant Patel as interim CEO; multiple executive departures
Prashant Patel re-appointed President, Interim-CEO, and Board member after August 2025 resignation.
-
CEO, COO, CFO resign at Wellgistics Health; interim CFO appointed
CEO Brian Norton, COO Tony Madsen, and CFO Mark DiSiena resigned effective Oct. 6, 2025.
-
Wellgistics Health removes two directors, appoints four new directors and a President
Rebecca Shanahan and Michael Peterson removed as directors effective Oct 1, 2025 by majority stockholder consent.
-
Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy
Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
-
Wellgistics Health to present at three investor conferences in September 2025
CEO Brian Norton will present at H.C. Wainwright 27th Global Investment Conference on Sept 8, 2025.
-
Wellgistics Health enters $1.3M loan and launches HubRx AI engine for prescription hub services
Entered $1.3M Business Loan with Agile Capital Funding; matures April 8, 2026; weekly payments of $58,500.
-
Wellgistics Health Q2 2025 results: H1 pro forma revenue $18.65M, debt conversion strengthens balance sheet
Pro forma revenue for H1 2025 was $18.65M, up 2.2% from $18.25M in H1 2024.
-
Wellgistics Health terminates $50M ELOC, President resigns, launches XRP payment program
Terminated $50M equity purchase agreement with Hudson Global Ventures without penalty; no termination fees.
-
Wellgistics Health converts $8.1M debt to equity, amends acquisition payment terms
Remaining $8.14M closing cash payment converted into 7,606,785 shares of common stock; reduces short-term debt.
-
Wellgistics Health dismisses Suri & Co., appoints UHY LLP as new auditor
Board approved dismissal of Suri & Co. on July 7, 2025, and engagement of UHY LLP effective same date.
-
Wellgistics Health posts revised investor presentation; no specific changes disclosed
Company updated its investor presentation on its website on May 15, 2025.
-
Wellgistics appoints Mark DiSiena as CFO; Vishnu Balu resigns
Appointment effective April 22, 2025; DiSiena succeeds Balu who served since April 2024.
-
Wellgistics Health converts $1.5M debt owed to CEO into 333,333 shares at $4.50 IPO price
Conversion of $1.5M cash payment due June 14, 2025 into 333,333 common shares at $4.50/share.
-
Wellgistics Health to acquire Peek Healthcare for $2M cash, $6M note, and shares
Merger: Peek acquired for $2M cash (adjusted) + $6M note (4.5% for 3 years) + 1,777,778 shares; 1,270,163 earn-out subject to $8.8M revenue target by Dec 2027.
-
Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M
Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.
-
Wellgistics Health enters consulting deal with Draper (100k shares) and reports SOC 2 Type 1 compliance
Entered consulting agreement with Draper, Inc. for investor relations and business development services; initial term 3 months, automatic monthly renewal.
-
Wellgistics Health appoints Brian Norton as CEO, partners with Protega to distribute ROXYBOND
Brian Norton promoted to CEO, succeeding Timothy Canning; no disagreement cited.
-
Wellgistics Health partners with Tollo Health to market medical foods for GLP-1 side effects and Long COVID
Consulting agreement with Hudson Global Ventures: $250,000 fee + 52,000 shares for 30-day advisory services.